Rockefeller Capital Management L.P. Sells 35,864 Shares of CRISPR Therapeutics AG $CRSP

Rockefeller Capital Management L.P. lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 24.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,667 shares of the company’s stock after selling 35,864 shares during the period. Rockefeller Capital Management L.P. owned 0.12% of CRISPR Therapeutics worth $5,908,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Mcguire Capital Advisors Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $25,000. Ramirez Asset Management Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $26,000. Rothschild Investment LLC grew its holdings in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after acquiring an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after acquiring an additional 382 shares during the period. Finally, Optiver Holding B.V. raised its position in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after acquiring an additional 210 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $54.92 on Friday. The stock has a market cap of $5.30 billion, a price-to-earnings ratio of -8.83 and a beta of 1.74. The firm’s 50-day moving average is $52.72 and its 200 day moving average is $53.07. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -4.89 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CRSP. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. Sanford C. Bernstein increased their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley set a $60.00 price objective on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $67.78.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.